© Rosalind Scientific LLC 2018-2022
© Rosalind Scientific LLC, 2018-2022
New Drug Hunter content, featured events and job postings straight to your inbox. Trusted by >3,500 drug hunters worldwide, unsubscribe anytime.
<< Back to May
topical BRAF inhibitor (gel) for EGFRi rash
Ph. I in mCRC with EGFRi-related rash
paradoxical activ. of MAPK to counter EGFRi
Cancer Discovery, May 25, 2021
Lutris-Parma, Tel Aviv, IL / MSKCC, NY
The Lutris-Parma topical BRAF inhibitor, LUT014, is intended to treat rash caused by EGFR inhibitors. Rash is a significant and common side effect of EGFR inhibitor treatment leading to worse…
Ask your company or librarian about a Drug Hunter membership to to see all summaries and get access to even more helpful information.